person · Reporting owner
Fitzgerald Kevin Joseph
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC.ALNY · Entity 3132 | CSO & EVP, Head of Research | March 04, 2026 | March 06, 2026 |
| Ovid Therapeutics Inc.OVID · Entity 5411 | Director | April 07, 2026 | April 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ALNYLAM PHARMACEUTICALS, INC.
Report date March 04, 2026 · Filed March 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 20,569 |
Ending reported balance
After 2026-03-05 transaction · row 12
12 source rows · reconciled sequenceRow 1 · 2026-03-04 · Sale · Disposed 29 · Balance 21,831 F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units. F2: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $318.27 to $319.27. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 2 · 2026-03-04 · Sale · Disposed 28 · Balance 21,803 F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units. F3: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $319.28 to $320.28. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 3 · 2026-03-04 · Sale · Disposed 59 · Balance 21,744 F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units. F4: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $320.33 to $321.33. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 4 · 2026-03-04 · Sale · Disposed 79 · Balance 21,665 F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units. F5: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $321.34 to $322.31. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 5 · 2026-03-04 · Sale · Disposed 96 · Balance 21,569 F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units. F6: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $322.36 to $323.36. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 6 · 2026-03-04 · Sale · Disposed 210 · Balance 21,359 F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units. F7: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $323.38 to $324.35. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 7 · 2026-03-04 · Sale · Disposed 75 · Balance 21,284 F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units. F8: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $324.39 to $325.38. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 8 · 2026-03-04 · Sale · Disposed 57 · Balance 21,227 F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units. F9: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $325.40 to $326.21. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 9 · 2026-03-05 · Sale · Disposed 124 · Balance 21,103 F10: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on August 14, 2025. F11: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $321.43 to $322.00. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 10 · 2026-03-05 · Sale · Disposed 233 · Balance 20,870 F10: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on August 14, 2025. F12: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $322.81 to $323.65. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 11 · 2026-03-05 · Sale · Disposed 148 · Balance 20,722 F10: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on August 14, 2025. F13: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $324.36 to $325.01. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 12 · 2026-03-05 · Sale · Disposed 153 · Balance 20,569 F10: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on August 14, 2025. F14: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $326.01 to $326.40. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
| Common StockSEC Table I · non-derivative | Indirectby Managed Account | 537 |
Reported balance
Holding disclosure · report date 2026-03-04 · row 13
Holding and transaction disclosures are not merged.
1 source rowRow 13 · Balance 537 F15: Reflects shares of ALNY common stock acquired by the Reporting Person under the issuer 401(k) plan as a result of the issuer 401(k) matching contribution program. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units.
F2: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $318.27 to $319.27. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F3: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $319.28 to $320.28. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F4: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $320.33 to $321.33. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F5: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $321.34 to $322.31. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F6: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $322.36 to $323.36. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F7: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $323.38 to $324.35. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F8: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $324.39 to $325.38. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F9: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $325.40 to $326.21. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F10: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on August 14, 2025.
F11: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $321.43 to $322.00. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F12: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $322.81 to $323.65. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F13: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $324.36 to $325.01. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F14: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $326.01 to $326.40. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F15: Reflects shares of ALNY common stock acquired by the Reporting Person under the issuer 401(k) plan as a result of the issuer 401(k) matching contribution program.
Ovid Therapeutics Inc.
Report date April 07, 2026 · Filed April 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 17,578 |
Reported balance
After 2026-04-07 transaction · row 1
1 source rowRow 1 · 2026-04-07 · Grant · Acquired 17,578 · Balance 17,578 F1: Represents a restricted stock unit ("RSU") award issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of an annual cash retainer for service on the Issuer's Board of Directors in the aggregate amount of $45,000. The RSUs vest 25% upon grant and 25% on each of June 30, 2026, September 30, 2026 and December 31, 2026, subject to the Reporting Person's continuous service through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a restricted stock unit ("RSU") award issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of an annual cash retainer for service on the Issuer's Board of Directors in the aggregate amount of $45,000. The RSUs vest 25% upon grant and 25% on each of June 30, 2026, September 30, 2026 and December 31, 2026, subject to the Reporting Person's continuous service through each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 07, 2026 Filed Apr 9, 2026 21:15 UTC | Ovid Therapeutics Inc. OVID · Entity 5411 | GrantCommon Stock | 17,578 | $2.56 | $44,999.68 |
DisclosureSEC source: 0001886431-26-000004 · form4-04092026_050401.xml · nonDerivative · entry 1 Fitzgerald Kevin Joseph · CIK 0001886431 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,578 F1 · kind: Represents a restricted stock unit ("RSU") award issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of an annual cash retainer for service on the Issuer's Board of Directors in the aggregate amount of $45,000. The RSUs vest 25% upon grant and 25% on each of June 30, 2026, September 30, 2026 and December 31, 2026, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| March 05, 2026 Filed Mar 6, 2026 21:11 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 153 | $326.24 | $49,914.72 |
DisclosureSEC source: 0001735276-26-000059 · edgardoc.xml · nonDerivative · entry 12 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,569 F10 · kind: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on August 14, 2025. F14 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $326.01 to $326.40. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 05, 2026 Filed Mar 6, 2026 21:11 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 148 | $324.60 | $48,040.80 |
DisclosureSEC source: 0001735276-26-000059 · edgardoc.xml · nonDerivative · entry 11 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,722 F10 · kind: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on August 14, 2025. F13 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $324.36 to $325.01. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 05, 2026 Filed Mar 6, 2026 21:11 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 233 | $323.25 | $75,317.25 |
DisclosureSEC source: 0001735276-26-000059 · edgardoc.xml · nonDerivative · entry 10 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,870 F10 · kind: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on August 14, 2025. F12 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $322.81 to $323.65. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 05, 2026 Filed Mar 6, 2026 21:11 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 124 | $321.81 | $39,904.44 |
DisclosureSEC source: 0001735276-26-000059 · edgardoc.xml · nonDerivative · entry 9 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,103 F10 · kind: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on August 14, 2025. F11 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $321.43 to $322.00. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 21:11 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 57 | $325.67 | $18,563.19 |
DisclosureSEC source: 0001735276-26-000059 · edgardoc.xml · nonDerivative · entry 8 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,227 F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units. F9 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $325.40 to $326.21. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 21:11 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 75 | $324.88 | $24,366.00 |
DisclosureSEC source: 0001735276-26-000059 · edgardoc.xml · nonDerivative · entry 7 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,284 F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units. F8 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $324.39 to $325.38. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 21:11 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 210 | $323.84 | $68,006.40 |
DisclosureSEC source: 0001735276-26-000059 · edgardoc.xml · nonDerivative · entry 6 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,359 F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units. F7 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $323.38 to $324.35. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 21:11 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 96 | $323.01 | $31,008.96 |
DisclosureSEC source: 0001735276-26-000059 · edgardoc.xml · nonDerivative · entry 5 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,569 F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units. F6 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $322.36 to $323.36. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 21:11 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 79 | $321.82 | $25,423.78 |
DisclosureSEC source: 0001735276-26-000059 · edgardoc.xml · nonDerivative · entry 4 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,665 F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units. F5 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $321.34 to $322.31. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 21:11 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 59 | $320.81 | $18,927.79 |
DisclosureSEC source: 0001735276-26-000059 · edgardoc.xml · nonDerivative · entry 3 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,744 F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units. F4 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $320.33 to $321.33. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 21:11 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 28 | $320.01 | $8,960.28 |
DisclosureSEC source: 0001735276-26-000059 · edgardoc.xml · nonDerivative · entry 2 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,803 F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units. F3 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $319.28 to $320.28. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 21:11 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 29 | $319.03 | $9,251.87 |
DisclosureSEC source: 0001735276-26-000059 · edgardoc.xml · nonDerivative · entry 1 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,831 F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units. F2 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $318.27 to $319.27. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 00:30 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 359 | $321.58 | $115,447.22 |
DisclosureSEC source: 0001735276-26-000051 · edgardoc.xml · nonDerivative · entry 15 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,860 F13 · kind: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on August 14, 2025. F17 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $321.36 to $321.84. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 00:30 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 722 | $320.51 | $231,408.22 |
DisclosureSEC source: 0001735276-26-000051 · edgardoc.xml · nonDerivative · entry 14 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,219 F13 · kind: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on August 14, 2025. F16 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $320.04 to $320.99. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 00:30 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 282 | $318.62 | $89,850.84 |
DisclosureSEC source: 0001735276-26-000051 · edgardoc.xml · nonDerivative · entry 13 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,941 F13 · kind: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on August 14, 2025. F15 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $318.25 to $318.90. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 00:30 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 289 | $316.55 | $91,482.95 |
DisclosureSEC source: 0001735276-26-000051 · edgardoc.xml · nonDerivative · entry 12 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,223 F13 · kind: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on August 14, 2025. F14 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $316.51 to $317.12. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 02, 2026 Filed Mar 5, 2026 00:30 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantStock Option (right to buy) · Derivative | 8,105 | $0.00 Strike: $325.07 | $0.00 |
DisclosureSEC source: 0001735276-26-000051 · edgardoc.xml · derivative · entry 17 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,105 Underlying: Common Stock · 8,105 shares Expires 2036-03-02 F19 · derivative.exercise_date: The stock option vests as to 25% of the shares on the first anniversary of the grant date and the remaining shares vest in equal installments at the end of each successive three-month period thereafter until the fourth anniversary of the grant date, subject to the Reporting Persons continuous service with the Issuer as of each such vesting date. Read SEC document |
| March 02, 2026 Filed Mar 5, 2026 00:30 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 37 | $332.64 | $12,307.68 |
DisclosureSEC source: 0001735276-26-000051 · edgardoc.xml · nonDerivative · entry 11 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,512 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations. F12 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $332.34 to $332.24. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 02, 2026 Filed Mar 5, 2026 00:30 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 94 | $331.93 | $31,201.42 |
DisclosureSEC source: 0001735276-26-000051 · edgardoc.xml · nonDerivative · entry 10 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,549 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations. F11 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $331.32 to $332.31. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 02, 2026 Filed Mar 5, 2026 00:30 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 81 | $330.85 | $26,798.85 |
DisclosureSEC source: 0001735276-26-000051 · edgardoc.xml · nonDerivative · entry 9 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,643 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations. F10 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $330.30 to $331.30. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 02, 2026 Filed Mar 5, 2026 00:30 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 170 | $329.71 | $56,050.70 |
DisclosureSEC source: 0001735276-26-000051 · edgardoc.xml · nonDerivative · entry 8 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,724 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations. F9 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $329.29 to $330.29. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 02, 2026 Filed Mar 5, 2026 00:30 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 100 | $328.71 | $32,871.00 |
DisclosureSEC source: 0001735276-26-000051 · edgardoc.xml · nonDerivative · entry 7 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,894 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations. F8 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $328.28 to $329.26. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 02, 2026 Filed Mar 5, 2026 00:30 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 329 | $327.67 | $107,803.43 |
DisclosureSEC source: 0001735276-26-000051 · edgardoc.xml · nonDerivative · entry 6 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,994 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations. F7 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $327.24 to $328.24. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 02, 2026 Filed Mar 5, 2026 00:30 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 392 | $326.81 | $128,109.52 |
DisclosureSEC source: 0001735276-26-000051 · edgardoc.xml · nonDerivative · entry 5 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,323 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations. F6 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $326.23 to $327.23. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 02, 2026 Filed Mar 5, 2026 00:30 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 258 | $325.63 | $84,012.54 |
DisclosureSEC source: 0001735276-26-000051 · edgardoc.xml · nonDerivative · entry 4 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,715 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations. F5 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $325.21 to $326.21. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 02, 2026 Filed Mar 5, 2026 00:30 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 90 | $324.65 | $29,218.50 |
DisclosureSEC source: 0001735276-26-000051 · edgardoc.xml · nonDerivative · entry 3 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,973 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations. F4 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $324.20 to $325.20. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 02, 2026 Filed Mar 5, 2026 00:30 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 47 | $323.62 | $15,210.14 |
DisclosureSEC source: 0001735276-26-000051 · edgardoc.xml · nonDerivative · entry 2 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,063 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations. F3 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $323.16 to $324.15. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 02, 2026 Filed Mar 5, 2026 00:30 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantCommon Stock | 3,688 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-26-000051 · edgardoc.xml · nonDerivative · entry 1 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,110 F1 · shares: These shares are represented by restricted stock units (RSUs) granted under the Second Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest over a three-year period, with one third vesting on each of the first, second and third anniversaries of the grant date, subject to the Reporting Persons continuous service with the Issuer as of each such vesting date. Read SEC document |
| February 26, 2026 Filed Mar 2, 2026 21:30 UTC | Ovid Therapeutics Inc. OVID · Entity 5411 | GrantEmployee Stock Option (Right to Buy) · Derivative | 65,000 | $0.00 Strike: $1.65 | $0.00 |
DisclosureSEC source: 0001886431-26-000002 · form4-03022026_040313.xml · derivative · entry 1 Fitzgerald Kevin Joseph · CIK 0001886431 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2036-02-25 F1 · derivative.exercise_date: The option will vest in full on February 26, 2027, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| February 23, 2026 Filed Feb 25, 2026 21:17 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantCommon Stock | 158 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-26-000032 · edgardoc.xml · nonDerivative · entry 1 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,422 F1 · kind: On February 23, 2026, the People, Culture, and Compensation Committee of the issuer approved the issuance of shares of Company common stock having an aggregate value of USD $100,000 to each employee who completes 20 consecutive years of employment. The shares issued and reported here on Form 4, net of the minimum statutory tax liability, were issued to the reporting person in recognition of 20 years of continuous employment on December 5, 2025. Read SEC document |
| February 17, 2026 Filed Feb 18, 2026 00:26 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 2,041 | $331.96 | $677,531.58 |
DisclosureSEC source: 0001735276-26-000026 · edgardoc.xml · nonDerivative · entry 3 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,264 F4 · kind: This transaction was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the Reporting Person on August 14, 2025. F5 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $329.10 to $334.51. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 13, 2026 Filed Feb 18, 2026 00:26 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 1,959 | $310.08 | $607,448.29 |
DisclosureSEC source: 0001735276-26-000026 · edgardoc.xml · nonDerivative · entry 2 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,305 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations. F3 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $302.55 to $314.60. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 12, 2026 Filed Feb 18, 2026 00:26 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantCommon Stock | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-26-000026 · edgardoc.xml · nonDerivative · entry 1 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,264 F1 · kind: On February 27, 2023, the reporting person was granted a performance-based stock unit (PSU) under the 2018 Stock Incentive Plan. The shares subject to the PSU vest based on the achievement of three specified performance measures. The shares reported were issued to the reporting person upon vesting of forty (40) percent of the shares subject to the PSU based on the issuer publicly reporting the achievement of non-GAAP operating income for fiscal year 2025 on February 12, 2026, as determined by the People, Culture and Compensation Committee of the Issuer Board of Directors. Read SEC document |
| January 13, 2026 Filed Jan 14, 2026 21:21 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 122 | $374.33 | $45,668.26 |
DisclosureSEC source: 0001735276-26-000011 · edgardoc.xml · nonDerivative · entry 28 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,264 F22 · kind: This transaction was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the Reporting Person on August 14, 2025. F28 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $374.28 to $374.66. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 13, 2026 Filed Jan 14, 2026 21:21 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 280 | $372.93 | $104,420.40 |
DisclosureSEC source: 0001735276-26-000011 · edgardoc.xml · nonDerivative · entry 27 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,386 F22 · kind: This transaction was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the Reporting Person on August 14, 2025. F27 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $372.70 to $373.11. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 13, 2026 Filed Jan 14, 2026 21:21 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 485 | $371.24 | $180,051.40 |
DisclosureSEC source: 0001735276-26-000011 · edgardoc.xml · nonDerivative · entry 26 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,666 F22 · kind: This transaction was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the Reporting Person on August 14, 2025. F26 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $370.52 to $371.47. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 13, 2026 Filed Jan 14, 2026 21:21 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 644 | $370.00 | $238,280.00 |
DisclosureSEC source: 0001735276-26-000011 · edgardoc.xml · nonDerivative · entry 25 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,151 F22 · kind: This transaction was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the Reporting Person on August 14, 2025. F25 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $369.36 to $370.35. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 13, 2026 Filed Jan 14, 2026 21:21 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 562 | $368.76 | $207,243.12 |
DisclosureSEC source: 0001735276-26-000011 · edgardoc.xml · nonDerivative · entry 24 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,795 F22 · kind: This transaction was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the Reporting Person on August 14, 2025. F24 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $368.25 to $369.23. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 13, 2026 Filed Jan 14, 2026 21:21 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 197 | $367.52 | $72,401.44 |
DisclosureSEC source: 0001735276-26-000011 · edgardoc.xml · nonDerivative · entry 23 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,357 F22 · kind: This transaction was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the Reporting Person on August 14, 2025. F23 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $367.18 to $367.96. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 21:21 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 15 | $377.82 | $5,667.30 |
DisclosureSEC source: 0001735276-26-000011 · edgardoc.xml · nonDerivative · entry 22 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,554 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations. Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 21:21 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 19 | $375.65 | $7,137.35 |
DisclosureSEC source: 0001735276-26-000011 · edgardoc.xml · nonDerivative · entry 21 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,569 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations. Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 21:21 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 14 | $374.44 | $5,242.16 |
DisclosureSEC source: 0001735276-26-000011 · edgardoc.xml · nonDerivative · entry 20 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,588 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations. F21 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $374.08 to $374.89. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 21:21 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 2 | $372.46 | $744.92 |
DisclosureSEC source: 0001735276-26-000011 · edgardoc.xml · nonDerivative · entry 19 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,602 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations. F20 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $372.35 to $372.50. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 21:21 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 19 | $370.87 | $7,046.53 |
DisclosureSEC source: 0001735276-26-000011 · edgardoc.xml · nonDerivative · entry 18 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,604 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations. F19 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $370.43 to $371.23. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 21:21 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 40 | $369.48 | $14,779.20 |
DisclosureSEC source: 0001735276-26-000011 · edgardoc.xml · nonDerivative · entry 17 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,623 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations. F18 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $369.13 to $369.93. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 21:21 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 92 | $368.62 | $33,913.04 |
DisclosureSEC source: 0001735276-26-000011 · edgardoc.xml · nonDerivative · entry 16 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,663 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations. F17 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $368.09 to $369.08. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 21:21 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 41 | $367.40 | $15,063.40 |
DisclosureSEC source: 0001735276-26-000011 · edgardoc.xml · nonDerivative · entry 15 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,755 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations. F16 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $367.04 to $368.00. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 21:21 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 50 | $366.41 | $18,320.50 |
DisclosureSEC source: 0001735276-26-000011 · edgardoc.xml · nonDerivative · entry 14 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,796 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations. F15 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $366.03 to $366.96. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 21:21 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 220 | $365.56 | $80,423.20 |
DisclosureSEC source: 0001735276-26-000011 · edgardoc.xml · nonDerivative · entry 13 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,846 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations. F14 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $365.01 to $366.01. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.